Fractyl Health (GUTS) Return on Capital Employed (2024 - 2026)
Fractyl Health (GUTS) reported Return on Capital Employed of 97.78% for Q1 2026, up 2826.0% year-on-year from 3.34% in Q1 2025, and little changed quarter-over-quarter from 97.29% in Q4 2025.
Fractyl Health (GUTS) has 3 years of Return on Capital Employed data on file, last reported at 97.78% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 2826.0% year-over-year to 97.78%; the trailing twelve-month figure through Mar 2026 stood at 97.78% (up 2826.0% YoY), and the FY2025 full-year result was 100.42%, up 2882.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 97.78%, roughly flat from 97.29% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 50.73% in Q2 2024 and bottomed at 196.96% in Q2 2025.
- A 3-year average of 103.38% and a median of 97.29% in 2025 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed slumped 14623 bps in 2025 and surged 2826 bps in 2026, its largest moves.
- Tracing GUTS's Return on Capital Employed over 3 years: stood at 95.71% in 2024, then retreated by 2 bps to 97.29% in 2025, then declined by 0 bps to 97.78% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 97.78%, 97.29%, and 142.16% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 21.10% |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 10.19% |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 20.34% |
| 10 | Fractyl Health | 19.24 Mn | 19.24 Mn | - | -97.78% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -97.78% |
| Dec 31, 2025 | -97.29% |
| Sep 30, 2025 | -142.16% |
| Jun 30, 2025 | -196.96% |
| Mar 31, 2025 | -126.04% |
| Dec 31, 2024 | -95.71% |
| Sep 30, 2024 | -67.21% |
| Jun 30, 2024 | -50.73% |
| Mar 31, 2024 | -56.54% |